Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 16/20 | 0.70 |
| ▸ | HTR2A | P28223 | 15/20 | 0.70 |
| ▸ | HTR2B | P41595 | 11/20 | 0.65 |
| ▸ | HTR6 | P50406 | 3/20 | 0.47 |
| ▸ | HTR1A | P08908 | 2/20 | 0.47 |
| ▸ | DRD1 | P21728 | 1/20 | 0.47 |
| ▸ | HTR1D | P28221 | 1/20 | 0.47 |
| ▸ | HTR1B | P28222 | 1/20 | 0.47 |
| ▸ | HTR1E | P28566 | 1/20 | 0.47 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.47 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.47 |
| ▸ | HTR7 | P34969 | 1/20 | 0.47 |
| ▸ | DRD3 | P35462 | 1/20 | 0.47 |
| ▸ | HTR5A | P47898 | 1/20 | 0.47 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.39 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.39 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.39 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29936591 | 1.00 | HTR2C (0.70) | HTR2CHTR2AHTR2BHTR6HTR1A | |
| SCHEMBL29361303 | 0.83 | HTR2C (0.75) | HTR2CHTR2AHTR2BHTR6HTR1A | |
| SCHEMBL23723408 | 0.83 | HTR2C (0.75) | HTR2CHTR2AHTR2BHTR6HTR1A | |
| SCHEMBL13592811 | 0.83 | HTR2A (1.00) | HTR2CHTR2AHTR2BHTR6HTR1A | |
| SCHEMBL25662706 | 0.82 | HTR2C (0.58) | HTR2CHTR2AHTR2BHTR6HTR1A | |
| SCHEMBL13592813 | 0.81 | HTR2A (0.85) | HTR2CHTR2AHTR2BHTR6HTR1A | |
| SCHEMBL30808108 | 0.80 | HTR2C (0.74) | HTR2CHTR2AHTR2BHTR6HTR1A | |
| SCHEMBL23805226 | 0.79 | HTR2A (1.00) | HTR2CHTR2AHTR2BHTR6HTR1A | |
| SCHEMBL23805259 | 0.79 | HTR2C (0.72) | HTR2CHTR2AHTR2BHTR6HTR1A | |
| SCHEMBL30808131 | 0.78 | HTR2C (0.67) | HTR2CHTR2AHTR2BHTR6HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250388611-A1 | PSILOCIN DERIVATIVES AS SEROTONERGIC PSYCHEDELIC AGENTS FOR THE TREATMENT OF CNS DISORDERS | MINDSET PHARMA, INC. (CA) | 2025-12-25 | — | — | US | disclosed |
| US-12054505-B2 | Psilocin derivatives as serotonergic psychedelic agents for the treatment of CNS disorders | MINDSET PHARMA INC. (CA) | 2024-08-06 | — | — | US | disclosed |
| US-20230203070-A1 | PSILOCIN DERIVATIVES AS SEROTONERGIC PSYCHEDELIC AGENTS FOR THE TREATMENT OF CNS DISORDERS | MINDSET PHARMA INC. (CA) | 2023-06-29 | — | — | US | disclosed |
| US-20230203070-A1 | PSILOCIN DERIVATIVES AS SEROTONERGIC PSYCHEDELIC AGENTS FOR THE TREATMENT OF CNS DISORDERS | MINDSET PHARMA INC. (CA) | 2023-06-29 | — | — | US | disclosed |
| US-20230203070-A1 | PSILOCIN DERIVATIVES AS SEROTONERGIC PSYCHEDELIC AGENTS FOR THE TREATMENT OF CNS DISORDERS | MINDSET PHARMA INC. (CA) | 2023-06-29 | — | — | US | disclosed |
| US-20230167141-A1 | PSILOCIN DERIVATIVES AS SEROTONERGIC PSYCHEDELIC AGENTS FOR THE TREATMENT OF CNS DISORDERS | MINDSET PHARMA INC. (CA) | 2023-06-01 | — | — | US | disclosed |
| US-20230167141-A1 | PSILOCIN DERIVATIVES AS SEROTONERGIC PSYCHEDELIC AGENTS FOR THE TREATMENT OF CNS DISORDERS | MINDSET PHARMA INC. (CA) | 2023-06-01 | — | — | US | disclosed |
| US-20230167141-A1 | PSILOCIN DERIVATIVES AS SEROTONERGIC PSYCHEDELIC AGENTS FOR THE TREATMENT OF CNS DISORDERS | MINDSET PHARMA INC. (CA) | 2023-06-01 | — | — | US | disclosed |
| US-20230118872-A1 | PSILOCIN DERIVATIVES AS SEROTONERGIC PSYCHEDELIC AGENTS FOR THE TREATMENT OF CNS DISORDERS | MINDSET PHARMA INC. (CA) | 2023-04-20 | — | — | US | disclosed |
| US-20230118872-A1 | PSILOCIN DERIVATIVES AS SEROTONERGIC PSYCHEDELIC AGENTS FOR THE TREATMENT OF CNS DISORDERS | MINDSET PHARMA INC. (CA) | 2023-04-20 | — | — | US | disclosed |
| US-11597738-B2 | Psilocin derivatives as serotonergic psychedelic agents for the treatment of CNS disorders | MINDSET PHARMA INC. (CA) | 2023-03-07 | — | — | US | disclosed |
| US-11591353-B2 | Psilocin derivatives as serotonergic psychedelic agents for the treatment of CNS disorders | MINDSET PHARMA INC. (CA) | 2023-02-28 | — | — | US | disclosed |
| US-11591353-B2 | Psilocin derivatives as serotonergic psychedelic agents for the treatment of CNS disorders | MINDSET PHARMA INC. (CA) | 2023-02-28 | — | — | US | disclosed |
| EP-4100391-A1 | PSILOCIN DERIVATIVES AS SEROTONERGIC PSYCHEDELIC AGENTS FOR THE TREATMENT OF CNS DISORDERS | Mindset Pharma Inc. (CA) | 2022-12-14 | — | — | EP | disclosed |
| CN-115397810-A | Silodosin derivatives as serotonergic hallucinogens for the treatment of CNS disorders | 明德赛特制药公司 | 2022-11-25 | — | — | CN | disclosed |
| US-20220324889-A1 | PSILOCIN DERIVATIVES AS SEROTONERGIC PSYCHEDELIC AGENTS FOR THE TREATMENT OF CNS DISORDERS | MINDSET PHARMA INC. (CA) | 2022-10-13 | — | — | US | disclosed |
| US-20220024956-A1 | PSILOCIN DERIVATIVES AS SEROTONERGIC PSYCHEDELIC AGENTS FOR THE TREATMENT OF CNS DISORDERS | MINDSET PHARMA INC. (CA) | 2022-01-27 | — | — | US | disclosed |
| US-20220024956-A1 | PSILOCIN DERIVATIVES AS SEROTONERGIC PSYCHEDELIC AGENTS FOR THE TREATMENT OF CNS DISORDERS | MINDSET PHARMA INC. (CA) | 2022-01-27 | — | — | US | disclosed |
| WO-2021155470-A1 | PSILOCIN DERIVATIVES AS SEROTONERGIC PSYCHEDELIC AGENTS FOR THE TREATMENT OF CNS DISORDERS | MINDSET PHARMA INC. (CA) | 2021-08-12 | — | — | WO | disclosed |
| WO-2021155470-A1 | PSILOCIN DERIVATIVES AS SEROTONERGIC PSYCHEDELIC AGENTS FOR THE TREATMENT OF CNS DISORDERS | MINDSET PHARMA INC. (CA) | 2021-08-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220324889-A1 | PSILOCIN DERIVATIVES AS SEROTONERGIC PSYCHEDELIC AGENTS FOR THE TREATMENT OF CNS DISORDERS | HTR1A, HTR6, HTR1B | HTR2C 7/4885HTR2A 4/4885HTR2B 13/4885 |
| US-20230118872-A1 | PSILOCIN DERIVATIVES AS SEROTONERGIC PSYCHEDELIC AGENTS FOR THE TREATMENT OF CNS DISORDERS | HTR1A, HTR6, HTR1B | HTR2C 7/4885HTR2A 4/4885HTR2B 13/4885 |
| US-20220024956-A1 | PSILOCIN DERIVATIVES AS SEROTONERGIC PSYCHEDELIC AGENTS FOR THE TREATMENT OF CNS DISORDERS | HTR1A, HTR6, HTR1B | HTR2C 7/4885HTR2A 4/4885HTR2B 13/4885 |
| US-12054505-B2 | Psilocin derivatives as serotonergic psychedelic agents for the treatment of CNS disorders | HTR1A, HTR6, HTR1B | HTR2C 7/4885HTR2A 4/4885HTR2B 13/4885 |
| US-11597738-B2 | Psilocin derivatives as serotonergic psychedelic agents for the treatment of CNS disorders | HTR1A, HTR6, HTR1B | HTR2C 7/4885HTR2A 4/4885HTR2B 13/4885 |
| US-20230203070-A1 | PSILOCIN DERIVATIVES AS SEROTONERGIC PSYCHEDELIC AGENTS FOR THE TREATMENT OF CNS DISORDERS | HTR1A, HTR6, HTR1B | HTR2C 7/4885HTR2A 4/4885HTR2B 13/4885 |
| US-11591353-B2 | Psilocin derivatives as serotonergic psychedelic agents for the treatment of CNS disorders | HTR1A, HTR6, HTR1B | HTR2C 7/4885HTR2A 4/4885HTR2B 13/4885 |
| US-20250388611-A1 | PSILOCIN DERIVATIVES AS SEROTONERGIC PSYCHEDELIC AGENTS FOR THE TREATMENT OF CNS DISORDERS | HTR6, CNR1, HTR1D | HTR2C 5/4885HTR2A 16/4885HTR2B 28/4885 |
| US-20230167141-A1 | PSILOCIN DERIVATIVES AS SEROTONERGIC PSYCHEDELIC AGENTS FOR THE TREATMENT OF CNS DISORDERS | HTR1A, HTR6, HTR1B | HTR2C 7/4885HTR2A 4/4885HTR2B 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.